Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.

Saved in:
Bibliographic Details
Title: Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.
Authors: Luo N; Department of Anatomy and Histology, School of Medicine, Nankai University, Tianjin, China.; Departments of Medicine, Vanderbilt University Medical Center, Nashville TN, USA., Formisano L; Departments of Medicine, Vanderbilt University Medical Center, Nashville TN, USA., Gonzalez-Ericsson PI; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville TN, USA., Sanchez V; Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville TN, USA., Dean PT; Departments of Medicine, Vanderbilt University Medical Center, Nashville TN, USA., Opalenik SR; Departments of Medicine, Vanderbilt University Medical Center, Nashville TN, USA., Sanders ME; Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville TN, USA., Cook RS; Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville TN, USA.; Cancer Biology Program, Vanderbilt University Medical Center, Nashville TN, USA.; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville TN, USA.; Department of Biomedical Engineering, Vanderbilt University Medical Center, Nashville TN., Arteaga CL; Departments of Medicine, Vanderbilt University Medical Center, Nashville TN, USA.; Department of Biomedical Engineering, Vanderbilt University Medical Center, Nashville TN., Johnson DB; Departments of Medicine, Vanderbilt University Medical Center, Nashville TN, USA., Balko JM; Departments of Medicine, Vanderbilt University Medical Center, Nashville TN, USA.; Cancer Biology Program, Vanderbilt University Medical Center, Nashville TN, USA.; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville TN, USA.
Source: Oncoimmunology [Oncoimmunology] 2018 Mar 06; Vol. 7 (6), pp. e1438106. Date of Electronic Publication: 2018 Mar 06 (Print Publication: 2018).
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Print ISSN: 2162-4011 (Print) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 29872580
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Luo+N%22">Luo N</searchLink>; Department of Anatomy and Histology, School of Medicine, Nankai University, Tianjin, China.; Departments of Medicine, Vanderbilt University Medical Center, Nashville TN, USA.<br /><searchLink fieldCode="AU" term="%22Formisano+L%22">Formisano L</searchLink>; Departments of Medicine, Vanderbilt University Medical Center, Nashville TN, USA.<br /><searchLink fieldCode="AU" term="%22Gonzalez-Ericsson+PI%22">Gonzalez-Ericsson PI</searchLink>; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville TN, USA.<br /><searchLink fieldCode="AU" term="%22Sanchez+V%22">Sanchez V</searchLink>; Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville TN, USA.<br /><searchLink fieldCode="AU" term="%22Dean+PT%22">Dean PT</searchLink>; Departments of Medicine, Vanderbilt University Medical Center, Nashville TN, USA.<br /><searchLink fieldCode="AU" term="%22Opalenik+SR%22">Opalenik SR</searchLink>; Departments of Medicine, Vanderbilt University Medical Center, Nashville TN, USA.<br /><searchLink fieldCode="AU" term="%22Sanders+ME%22">Sanders ME</searchLink>; Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville TN, USA.<br /><searchLink fieldCode="AU" term="%22Cook+RS%22">Cook RS</searchLink>; Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville TN, USA.; Cancer Biology Program, Vanderbilt University Medical Center, Nashville TN, USA.; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville TN, USA.; Department of Biomedical Engineering, Vanderbilt University Medical Center, Nashville TN.<br /><searchLink fieldCode="AU" term="%22Arteaga+CL%22">Arteaga CL</searchLink>; Departments of Medicine, Vanderbilt University Medical Center, Nashville TN, USA.; Department of Biomedical Engineering, Vanderbilt University Medical Center, Nashville TN.<br /><searchLink fieldCode="AU" term="%22Johnson+DB%22">Johnson DB</searchLink>; Departments of Medicine, Vanderbilt University Medical Center, Nashville TN, USA.<br /><searchLink fieldCode="AU" term="%22Balko+JM%22">Balko JM</searchLink>; Departments of Medicine, Vanderbilt University Medical Center, Nashville TN, USA.; Cancer Biology Program, Vanderbilt University Medical Center, Nashville TN, USA.; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville TN, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101570526%22">Oncoimmunology</searchLink> [Oncoimmunology] 2018 Mar 06; Vol. 7 (6), pp. e1438106. <i>Date of Electronic Publication: </i>2018 Mar 06 (<i>Print Publication: </i>2018).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101570526 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2162-4011 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221624011%22">21624011 </searchLink><i>NLM ISO Abbreviation: </i>Oncoimmunology <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=29872580
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/2162402X.2018.1438106
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e1438106
    Titles:
      – TitleFull: Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Luo N
      – PersonEntity:
          Name:
            NameFull: Formisano L
      – PersonEntity:
          Name:
            NameFull: Gonzalez-Ericsson PI
      – PersonEntity:
          Name:
            NameFull: Sanchez V
      – PersonEntity:
          Name:
            NameFull: Dean PT
      – PersonEntity:
          Name:
            NameFull: Opalenik SR
      – PersonEntity:
          Name:
            NameFull: Sanders ME
      – PersonEntity:
          Name:
            NameFull: Cook RS
      – PersonEntity:
          Name:
            NameFull: Arteaga CL
      – PersonEntity:
          Name:
            NameFull: Johnson DB
      – PersonEntity:
          Name:
            NameFull: Balko JM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 06
              M: 03
              Text: 2018 Mar 06
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-print
              Value: 2162-4011
          Numbering:
            – Type: volume
              Value: 7
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Oncoimmunology
              Type: main
ResultId 1